NASDAQ:ZYNE

Zynerba Pharmaceuticals News Headlines

$4.08
-0.33 (-7.48 %)
(As of 04/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.02
Now: $4.08
$4.38
50-Day Range
$3.83
MA: $4.58
$7.03
52-Week Range
$3.12
Now: $4.08
$9.00
Volume1.49 million shs
Average Volume4.77 million shs
Market Capitalization$168.31 million
P/E RatioN/A
Dividend YieldN/A
Beta2.83

Headlines

Zynerba Pharmaceuticals (NASDAQ ZYNE) News Headlines Today

SourceHeadline
Short Interest in Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Decreases By 23.7%Short Interest in Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Decreases By 23.7%
americanbankingnews.com - April 18 at 1:56 AM
Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Society of Biological Psychiatry 2021 Virtual MeetingZynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting
finance.yahoo.com - April 15 at 8:38 AM
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Receives Consensus Rating of "Buy" from BrokeragesZynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Receives Consensus Rating of "Buy" from Brokerages
americanbankingnews.com - April 9 at 8:44 AM
Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare ConferenceZynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference
finance.yahoo.com - April 6 at 7:51 AM
-$0.25 Earnings Per Share Expected for Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) This Quarter-$0.25 Earnings Per Share Expected for Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) This Quarter
americanbankingnews.com - April 6 at 4:10 AM
Zynerba (ZYNE) Alert: Shareholder Class Action...Zynerba (ZYNE) Alert: Shareholder Class Action...
benzinga.com - March 28 at 1:28 PM
Zynerba (ZYNE) Alert: Shareholder Class Action Survives Motion to Dismiss; Should Management be Held Accountable for Investors Losses? Contact Johnson FistelZynerba (ZYNE) Alert: Shareholder Class Action Survives Motion to Dismiss; Should Management be Held Accountable for Investors Losses? Contact Johnson Fistel
finance.yahoo.com - March 28 at 8:28 AM
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?
finance.yahoo.com - March 12 at 1:13 PM
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational HighlightsZynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
finance.yahoo.com - March 10 at 8:26 AM
Global Fibromyalgia Drugs Market Assessment 2021-2026 - Impact of COVID-19, Case Study Analysis, Key Opportunities and Major PlayersGlobal Fibromyalgia Drugs Market Assessment 2021-2026 - Impact of COVID-19, Case Study Analysis, Key Opportunities and Major Players
marketwatch.com - March 5 at 2:35 PM
Zynerba Pharmaceuticals to Participate in the 33rd Annual ROTH ConferenceZynerba Pharmaceuticals to Participate in the 33rd Annual ROTH Conference
finance.yahoo.com - March 4 at 12:40 PM
4 Penny Stocks to Watch in March If You Like Biotech, Are They A Buy?4 Penny Stocks to Watch in March If You Like Biotech, Are They A Buy?
marketwatch.com - March 3 at 5:14 AM
Marijuana as medicine: the other cannabinoid pharma playersMarijuana as medicine: the other cannabinoid pharma players
seekingalpha.com - February 8 at 8:36 AM
GW Pharma Soars To Record High On Jazzs $7.2 Billion Takeover DealGW Pharma Soars To Record High On Jazz's $7.2 Billion Takeover Deal
finance.yahoo.com - February 3 at 2:04 PM
Zynerba Pharmaceuticals to Present at Two January Virtual Investor ConferencesZynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences
finance.yahoo.com - January 4 at 9:51 AM
ZYNE Dec 2020 7.500 putZYNE Dec 2020 7.500 put
sg.finance.yahoo.com - December 23 at 10:37 PM
Heres What We Think About Zynerba Pharmaceuticals (NASDAQ:ZYNE) CEO PayHere's What We Think About Zynerba Pharmaceuticals' (NASDAQ:ZYNE) CEO Pay
finance.yahoo.com - December 23 at 12:36 PM
Zynerba meets with FDA as development of its Fragile X syndrome program using Zygel advancesZynerba meets with FDA as development of its Fragile X syndrome program using Zygel advances
proactiveinvestors.com - December 19 at 11:41 PM
Zynerba provides progress report on its potential Fragile X syndrome therapyZynerba provides progress report on its potential Fragile X syndrome therapy
bizjournals.com - December 17 at 6:26 PM
ZYNE : Single Trial To Be Conducted In Patients With Fragile X Syndrome To Confirm Positive ResultsZYNE : Single Trial To Be Conducted In Patients With Fragile X Syndrome To Confirm Positive Results
markets.businessinsider.com - December 17 at 8:23 AM
Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X SyndromeZynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome
finance.yahoo.com - December 17 at 8:23 AM
Shuman, Glenn & Stecker Investigates Zynerba Pharmaceuticals, Inc.Shuman, Glenn & Stecker Investigates Zynerba Pharmaceuticals, Inc.
finance.yahoo.com - December 9 at 4:41 PM
The Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of InvestorsThe Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of Investors
finance.yahoo.com - December 7 at 5:27 PM
The Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of InvestorsThe Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of Investors
finance.yahoo.com - December 7 at 5:27 PM
Zynerba Pharmaceuticals Presents New Data in Two Posters at the 2020 Annual Meeting of the American Epilepsy Society (AES)Zynerba Pharmaceuticals Presents New Data in Two Posters at the 2020 Annual Meeting of the American Epilepsy Society (AES)
finance.yahoo.com - December 4 at 4:49 PM
Is Zynerba Pharmaceuticals (ZYNE) A Good Stock To Buy Now?Is Zynerba Pharmaceuticals (ZYNE) A Good Stock To Buy Now?
finance.yahoo.com - December 3 at 10:52 PM
Zynerba Pharmaceuticals EPS beats by $0.12Zynerba Pharmaceuticals EPS beats by $0.12
seekingalpha.com - November 9 at 8:24 AM
Zynerba Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational HighlightsZynerba Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights
finance.yahoo.com - November 9 at 8:24 AM
Zynerba Zygel Remains A Huge Part Of The Companys Pipeline Despite SetbackZynerba Zygel Remains A Huge Part Of The Company's Pipeline Despite Setback
seekingalpha.com - October 29 at 7:04 AM
New data shows Zynerbas ZYN002 positive effect in autism studyNew data shows Zynerba's ZYN002 positive effect in autism study
seekingalpha.com - October 15 at 7:43 PM
Zynerba Pharmaceuticals Announces Oral Presentations at the Virtual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Annual MeetingZynerba Pharmaceuticals Announces Oral Presentations at the Virtual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Annual Meeting
markets.businessinsider.com - October 8 at 9:38 AM
We're Keeping An Eye On Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn RateWe're Keeping An Eye On Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Rate
finance.yahoo.com - September 23 at 6:55 PM
Zynerba Pharmaceuticals (ZYNE) Jumps: Stock Rises 7.7%Zynerba Pharmaceuticals (ZYNE) Jumps: Stock Rises 7.7%
finance.yahoo.com - September 18 at 12:34 PM
Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion SyndromeZynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome
finance.yahoo.com - September 17 at 3:30 PM
Zynerba Pharmaceuticals Provides Update on Recent MilestonesZynerba Pharmaceuticals Provides Update on Recent Milestones
finance.yahoo.com - September 14 at 8:25 AM
Zynerba Pharmaceuticals to Present at Two Upcoming Virtual Investor ConferencesZynerba Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences
finance.yahoo.com - September 10 at 12:16 PM
Zynerba Pharmaceuticals Ireveals $77M on hand in 2Q results, says it can fund itself to 4Q 2021Zynerba Pharmaceuticals Ireveals $77M on hand in 2Q results, says it can fund itself to 4Q 2021
proactiveinvestors.com - August 12 at 3:39 AM
Zynerba Pharmaceuticals EPS misses by $0.33Zynerba Pharmaceuticals EPS misses by $0.33
seekingalpha.com - August 10 at 7:32 AM
Zynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational HighlightsZynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights
benzinga.com - August 10 at 7:32 AM
Zynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational HighlightsZynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights
finance.yahoo.com - August 10 at 7:32 AM
Zynerba Pharmaceuticals to Present at the Virtual 40th Annual Canaccord Genuity Growth ConferenceZynerba Pharmaceuticals to Present at the Virtual 40th Annual Canaccord Genuity Growth Conference
finance.yahoo.com - August 6 at 7:58 AM
Behavioral Therapy Market Size Forecast to Reach $187.4 Billion by 2025Behavioral Therapy Market Size Forecast to Reach $187.4 Billion by 2025
www.marketwatch.com - July 30 at 8:06 PM
New Reasons For GW Pharmaceuticals To Ride HighNew Reasons For GW Pharmaceuticals To Ride High
seekingalpha.com - July 13 at 12:27 PM
Main Line pharma firm pushing ahead with new drug candidate despite setbackMain Line pharma firm pushing ahead with new drug candidate despite setback
www.bizjournals.com - July 7 at 8:09 AM
Zynerbas Zygel Fails in Phase III Fragile X Syndrome StudyZynerba's Zygel Fails in Phase III Fragile X Syndrome Study
www.nasdaq.com - July 1 at 2:21 PM
Zynerba's Zygel Fails in Phase III Fragile X Syndrome StudyZynerba's Zygel Fails in Phase III Fragile X Syndrome Study
finance.yahoo.com - July 1 at 2:21 PM
BRIEF-Zynerba Pharmaceuticals Announces Top Line Results From Pivotal Connect-FX Trial Of ZygelBRIEF-Zynerba Pharmaceuticals Announces Top Line Results From Pivotal Connect-FX Trial Of Zygel
www.reuters.com - June 30 at 11:38 PM
Zynerba Cannabinoid Investors Must Now Refocus on Treating AutismZynerba Cannabinoid Investors Must Now Refocus on Treating Autism
www.msn.com - June 30 at 6:38 PM
Zynerbas Zygel flunks Fragile X studyZynerba's Zygel flunks Fragile X study
seekingalpha.com - June 30 at 8:37 AM
Zynerbas cannabis-based drug for rare genetic disorder fails studyZynerba's cannabis-based drug for rare genetic disorder fails study
uk.reuters.com - June 30 at 8:37 AM
This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.